Evidence map›Paper›PMID 29587629›Full record

ReviewBMC developmental biology2018

Comparative analysis of FKBP family protein: evaluation, structure, and function in mammals and Drosophila melanogaster.

George Ghartey-Kwansah, Zhongguang Li, Rui Feng, Liyang Wang, Xin Zhou, Frederic Z Chen, Meng Meng Xu, Odell Jones, Yulian Mu, Shawn Chen and 4 more

Abstract readComparative StudyReview
In one paragraph

Review in BMC developmental biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Proteomics analysis of soluble secreted proteins ofFrontiers in cellular and infection microbiology · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

George Ghartey-KwansahNational Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, Xi'an, 710062, China.
Zhongguang LiNational Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, Xi'an, 710062, China.
Rui FengNational Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, Xi'an, 710062, China.
Liyang WangNational Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, Xi'an, 710062, China.
Xin ZhouNational Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, Xi'an, 710062, China.
Frederic Z ChenChen Wellness Clinics, Wichita, KS, USA.
Meng Meng XuDepartment of Pharmacology, Duke University Medical Center, Durham, NC, USA.
Odell JonesUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Yulian MuState Key Laboratory for Animal Nutrition, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, China.
Shawn ChenChen Wellness Clinics, Wichita, KS, USA.
Joseph BryantUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Williams B IsaacsJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Jianjie MaOhio State University College of Medicine, Columbus, OH, USA.
Xuehong XuNational Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, Xi'an, 710062, China. xhx0708@snnu.edu.cn.ORCID 0000-0003-4565-780X

Funding

by the National Natural Science Foundation of China 31371256/31571273/31771277Ministry of Science and Technology of the People's Republic of China 2015CB943100the Foreign Distinguished Scientist Program from the National Department of Education MS2014SXSF038the National Department of Education Central Universities Research Fund GK20130100/201701005/GERP-17-45the Outstanding Doctoral Thesis fund X2014YB02/X2015YB05US Maryland Stem Cell Research Fund 2009MSCRFE008300
6 · The paper itself

Abstract

backgroundFK506-binding proteins (FKBPs) have become the subject of considerable interest in several fields, leading to the identification of several cellular and molecular pathways in which FKBPs impact prenatal development and pathogenesis of many human diseases. MAIN BODY: This analysis revealed differences between how mammalian and Drosophila FKBPs mechanisms function in relation to the immunosuppressant drugs, FK506 and rapamycin. Differences that could be used to design insect-specific pesticides. (1) Molecular phylogenetic analysis of FKBP family proteins revealed that the eight known Drosophila FKBPs share homology with the human FKBP12. This indicates a close evolutionary relationship, and possible origination from a common ancestor. (2) The known FKBPs contain FK domains, that is, a prolyl cis/trans isomerase (PPIase) domain that mediates immune suppression through inhibition of calcineurin. The dFKBP59, CG4735/Shutdown, CG1847, and CG5482 have a Tetratricopeptide receptor domain at the C-terminus, which regulates transcription and protein transportation. (3) FKBP51 and FKBP52 (dFKBP59), along with Cyclophilin 40 and protein phosphatase 5, function as Hsp90 immunophilin co-chaperones within steroid receptor-Hsp90 heterocomplexes. These immunophilins are potential drug targets in pathways associated with normal physiology and may be used to treat a variety of steroid-based diseases by targeting exocytic/endocytic cycling and vesicular trafficking. (4) By associating with presinilin, a critical component of the Notch signaling pathway, FKBP14 is a downstream effector of Notch activation at the membrane. Meanwhile, Shutdown associates with transposons in the PIWI-interacting RNA pathway, playing a crucial role in both germ cells and ovarian somas. Mutations in or silencing of dFKBPs lead to early embryonic lethality in Drosophila. Therefore, further understanding the mechanisms of FK506 and rapamycin binding to immunophilin FKBPs in endocrine, cardiovascular, and neurological function in both mammals and Drosophila would provide prospects in generating unique, insect specific therapeutics targeting the above cellular signaling pathways.

conclusionThis review will evaluate the functional roles of FKBP family proteins, and systematically summarize the similarities and differences between FKBP proteins in Drosophila and Mammals. Specific therapeutics targeting cellular signaling pathways will also be discussed.

Indexed as

Amino Acid SequenceAnimalsDrosophila melanogasterEvolution, MolecularHumansInsecticidesMammalsPhylogenyTacrolimus Binding ProteinsInsecticidesTacrolimus Binding ProteinsFK506-binding proteinHsp90Inositol 1, 4, 5-trisphosphateNotchPeptidyl-prolyl isomerasePhospholipase CRyanodine receptorTetratricopetide receptorTransient receptor potential

Identifiers

PMID29587629
PMCPMC5870485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.